Abeona Therapeutics Inc (NASDAQ:ABEO) Given Consensus Recommendation of “Hold” by Analysts

Abeona Therapeutics Inc (NASDAQ:ABEO) has earned a consensus recommendation of “Hold” from the nine analysts that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $15.75.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 30th. Maxim Group downgraded shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. ValuEngine raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Cantor Fitzgerald downgraded shares of Abeona Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, August 12th. Finally, Mizuho reaffirmed a “hold” rating and set a $4.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, September 4th.

A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Bank of America Corp DE grew its position in Abeona Therapeutics by 440.5% in the 4th quarter. Bank of America Corp DE now owns 26,689 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 21,751 shares during the period. BNP Paribas Arbitrage SA grew its position in Abeona Therapeutics by 21,590.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 6,477 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Abeona Therapeutics by 7.1% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 19,523 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,286 shares during the period. SG Americas Securities LLC grew its position in Abeona Therapeutics by 37.5% in the 1st quarter. SG Americas Securities LLC now owns 31,243 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 8,523 shares during the period. Finally, Alps Advisors Inc. grew its position in Abeona Therapeutics by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 115,800 shares of the biopharmaceutical company’s stock valued at $852,000 after purchasing an additional 5,002 shares during the period. 58.73% of the stock is owned by institutional investors and hedge funds.

Shares of ABEO stock traded down $0.15 during trading hours on Friday, hitting $2.99. 28,465 shares of the company were exchanged, compared to its average volume of 1,992,986. The firm has a market cap of $154.87 million, a P/E ratio of -2.53 and a beta of 1.93. Abeona Therapeutics has a fifty-two week low of $1.46 and a fifty-two week high of $14.70. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.54 and a current ratio of 2.54. The company has a 50 day simple moving average of $2.44 and a two-hundred day simple moving average of $5.49.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). Abeona Therapeutics had a negative return on equity of 59.99% and a negative net margin of 960.91%. As a group, sell-side analysts expect that Abeona Therapeutics will post -1.7 EPS for the current fiscal year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Recommended Story: Technical Indicators – What is a Golden Cross?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.